Filing scope and business context
The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2013 (fiscal second quarter of 2014), not a filing for Lite Strategy, Inc. or calendar-year 2012 Q2. The company is a development-stage oncology biotech with no commercial product revenue reported. Its programs include Pracinostat, ME-344 and PWT143; ME-143 had no further clinical studies planned.
Financial performance and position
Amounts below are in millions of dollars, except per-share data. The filing reports no revenue; margins therefore are not meaningful.
| Metric | Three months ended Dec. 31 | Six months ended Dec. 31 |
|---|---|---|
| 2013 operating expenses | $6.349 | $11.262 |
| 2012 operating expenses | $2.756 | $5.222 |
| 2013 net loss | $6.324 | $11.220 |
| 2012 net loss | $2.754 | $5.218 |
| 2013 basic and diluted loss per share | $0.32 | $0.60 |
| 2012 basic and diluted loss per share | $0.50 | $1.17 |
At December 31, 2013, cash and cash equivalents were $39.762 million and short-term investments were $20.001 million, totaling $59.763 million, versus $35.573 million in cash and no short-term investments at June 30, 2013. Current assets were $60.656 million; current liabilities were $2.428 million. The balance sheet shows no borrowings or other debt. Accumulated development-stage deficit was $107.517 million.
For the six months, operating cash use was $8.530 million (prior-year period: $4.647 million); investing cash use was $20.006 million, primarily purchases of U.S. government securities; financing provided $32.725 million, principally October 2013 offering proceeds. Cash increased $4.189 million over the period. Management said existing cash, cash equivalents and short-term investments were expected to fund operations through calendar 2015, subject to spending and development-plan changes.
Changes versus the prior comparable period
- Six-month net loss more than doubled to $11.220 million from $5.218 million; quarterly net loss rose to $6.324 million from $2.754 million.
- Six-month R&D expense increased to $7.502 million from $2.890 million, driven mainly by Pracinostat manufacturing and Phase II trials, ME-344 manufacturing and Phase I work, and increased staffing and share-based compensation.
- Six-month G&A expense increased to $3.760 million from $2.332 million, including share-based compensation of $1.596 million versus $0.527 million.
- In October 2013, the company sold 4.375 million shares at $8.00 per share, receiving $32.7 million net. Shares issued and outstanding rose to 21,495,071 at December 31 from 17,116,571 at June 30.
Outlook, commentary and risks
- Management expected R&D expense to increase during fiscal 2014, primarily for Pracinostat Phase II trials. It anticipated enrollment completion by June 2014 and topline results in December 2014 for a 100-patient Pracinostat/azacitidine Phase II MDS trial; preliminary data from two other Phase II trials were also anticipated by December 2014.
- The company planned to begin a Phase Ib ME-344 combination trial in small cell lung and ovarian cancers in calendar Q2 2014, and expected to complete PWT143 preclinical work supporting an IND filing by year-end 2014.
- Key uncertainties include clinical-trial success and timing, regulatory approvals, financing availability, manufacturing and third-party dependence, intellectual-property protection, competition and eventual commercialization. The company expects to seek additional capital or strategic partnerships in the future.
- Potential S*Bio milestone payments could total up to $75.2 million, subject to specified regulatory approvals and sales thresholds. The first stated milestone is $200,000 plus $500,000 in company stock upon first patient dosing in a Phase III or other pivotal trial. No amounts were accrued for potential future payments at December 31, 2013. CyDex arrangements also include future milestones and low-single-digit royalties on future sales of qualifying approved drugs.
- ME-344 Phase I results included a confirmed partial response in one small cell lung cancer patient; dose-limiting toxicities at higher doses included Grade 3 peripheral neuropathy, with angina and QTc prolongation also reported in individual patients.
- Share-based compensation was $2.350 million for the six months. Outstanding warrants included 4,526,361 shares exercisable at $3.12 through December 2017, among other warrants, representing potential dilution.
Most important facts for investors to verify
- Whether clinical trial enrollment, data readouts and the ME-344 and PWT143 development timelines remain on schedule.
- Whether the stated runway through calendar 2015 remains realistic given operating cash use and planned trial spending.
- Potential future financing needs, share dilution and warrant exercises.
- The conditions, timing and potential financial impact of S*Bio milestones and CyDex obligations.
- The filing identity and period: the source is MEI Pharma’s quarter ended December 31, 2013, despite the supplied metadata indicating a different company and period.